

Trial Designs: Ethical Considerations



- Is a $< 1\%$ risk of progression (e.g., death or hospitalization with oxygen requirement) acceptable for enrolling into a placebo-controlled trial (where approved or authorized COVID-19 therapies are prohibited)?

